Volpara was founded in 2009 to provide the most accurate breast-density measurement possible. By applying this work to breast screening, enhancing its ability to detect breast cancer early, Volpara seeks to fulfil its purpose of saving families from cancer.

Volpara’s software is designed to optimise the breast screening experience and improve outcomes for women. Its clinical decision-support tools help radiologists make informed and timely decisions about a woman's breast cancer risk and the need for additional imaging. To date, Volpara’s technology and services have been used by customers and/or research projects in 39 countries. Volpara’s software is supported by numerous patents, trademarks, and regulatory registrations, including FDA clearance, TGA and CE marking, and an unmatched volume of peer-reviewed publications. Its software platform is the most scientifically validated in the breast health industry and is the choice of leading clinical sites around the world.

Since listing on the ASX in April 2016, Volpara has raised A$132 million, including A$37 million in April/May 2020, and has made two significant acquisitions in MRS Systems, Inc. (patient tracking software), and CRA Health, LLC (risk and genetics software).

With offices in Seattle and Boston, Volpara is headquartered in Wellington, New Zealand.

2020

2019

2018